A photo of Marc Rothenberg.

Marc E. Rothenberg, MD, PhD

  • Director, Division of Allergy and Immunology
  • Director, Cincinnati Center for Eosinophilic Disorders
  • Professor, UC Department of Pediatrics



We know so much about the human body, yet the science of medicine holds many mysteries. This couldn’t be truer for allergic and immune conditions, many of which have origins in childhood and cause immense suffering.

In my clinical practice and laboratory at Cincinnati Children’s Hospital Medical Center, I am focused on solving the mysteries of allergic inflammatory disease, especially eosinophilic gastrointestinal disorders, or EGIDs.

I had the opportunity early in my training to work alongside wonderful mentors who supported me and my interests in this work. At Brandeis University, I worked under the guidance of the late Professor William P. Jencks, a renowned biochemist, and learned the basic tenets of scientific inquiry. Under the direction of Harvard Medical School’s Dr. Frank Austen, I conducted studies on eosinophil hematopoiesis and developed the first culture system for human eosinophils. During my post-doctoral training with Harvard’s renowned geneticist Dr. Philip Leder, I cloned the eotaxin chemokine.

These were such exciting times for me as a young scientist, and these positive training experiences formed the foundation on which I have built my own laboratory at Cincinnati Children’s.

Here, our mission is to improve the health and well-being of children with allergic and immune conditions. We do this through innovative research, outstanding clinical care, and education of the current and next generation of leaders in healthcare and research.

We take a multidisciplinary approach to our work and have developed preclinical models that have taught us more about the genetics, genomics, molecular immunology and biochemistry of eosinophilic diseases. We have also built translational experimental systems that help us better understand human disease. These approaches have laid the foundation for our clinical trials in patients.

My approach to patients is to provide the best care possible while learning from each patient through research.

With the support of my team, I have been awarded a National Institutes of Health Merit Award, the Cincinnati Children's Hospital Research Achievement Award, and have been elected as a member of both the American Society for Clinical Investigation and the American Association for the Advancement of Science. I am President-Elect of the International Eosinophil Society and hope to use this experience to positively influence future research and care for eosinophilic disease.

I am pleased to see my research advance the understanding and treatment of allergic diseases. At the same time, I know that we need to do much more.

I dream of a day when we can re-educate the immune system to reverse the food hypersensitivity that drives EGIDs and that such treatments will be readily affordable and available.

I am fortunate at Cincinnati Children’s to be surrounded by a dedicated and like-minded team of scientists and clinicians – all determined to develop the best treatment for eosinophilic diseases. And I am forever grateful to all of the children, parents, families and adults who partner with us in our efforts to conquer eosinophilic diseases. I am also grateful to my wife and my parents for their love, support and encouragement.

We have accomplished so much, and I look forward to seeing how our contributions can contribute to positively impacting the emerging breakthroughs in diagnosing and treating patients.

MD, PhD: Harvard Medical School, Cambridge, MA, 1990.

Residency: Pediatrics, Children's Hospital, Boston, MA, 1991-1992.

Fellowship: Immunology / Allergy, Children's Hospital, Boston, MA, 1992-1994; Hematology / Oncology, Children's Hospital and Dana Farber Cancer Institute, Boston, MA, 1992-1995.

Certification: National Board of Medical Examiners, 1991; Board of Registration in Medicine, MA, 1992; American Board of Pediatrics, 1995, 2001, 2008; Ohio State Medical Board, 1997; American Board of Allergy and Immunology, 1997, 2006.


Eosinophilia; eosinophilic disorders; asthma; allergy; food allergy


Services and Specialties

Allergy and Immunology, Eosinophilic Disorders


Eosinophils; chemokines

Research Areas

Allergy and Immunology, Eosinophilic Disorders, Global Health

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information



Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Kliewer, KL; Murray-Petzold, C; Collins, MH; Abonia, JP; Bolton, SM; DiTommaso, LA; Martin, LJ; Zhang, X; Mukkada, VA; Putnam, PE; Lyles, JL; Shoda, T; Klion, AD; Rothenberg, ME. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.


One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Kliewer, KL; Gonsalves, N; Dellon, ES; Katzka, DA; Abonia, JP; Aceves, SS; Arva, NC; Besse, JA; Bonis, PA; Caldwell, JM; Yang, GY; Zhang, X; Furuta, GT; Rothenberg, ME. The Lancet Gastroenterology and Hepatology. 2023; 8:408-421.


Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. Dellon, ES; Rothenberg, ME; Collins, MH; Hirano, I; Chehade, M; Bredenoord, AJ; Lucendo, AJ; Spergel, JM; Aceves, S; Sun, X; Shumel, B; Maloney, J; Giannelou, A; Shabbir, A. The New England journal of medicine. 2022; 387:2317-2330.


Desmoplakin and periplakin genetically and functionally contribute to eosinophilic esophagitis. Shoda, T; Kaufman, KM; Wen, T; Caldwell, JM; Osswald, GA; Purnima, P; Zimmermann, N; Collins, MH; Rehn, K; Foote, H; Mukkada, VA; Putnam, PE; Martin, LJ; Rothenberg, ME. Nature Communications. 2021; 12:6795.


Environmental allergens trigger type 2 inflammation through ripoptosome activation. Brusilovsky, M; Rochman, M; Rochman, Y; Caldwell, JM; Mack, LE; Felton, JM; Habel, JE; Porollo, A; Pasare, C; Rothenberg, ME. Nature Immunology. 2021; 22:1316-1326.


Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis. Azouz, NP; Klingler, AM; Pathre, P; Besse, JA; Ben Baruch-Morgenstern, N; Ballaban, AY; Osswald, GA; Brusilovsky, M; Habel, JE; Caldwell, JM; Ynga-Durand, MA; Abonia, PJ; Hu, Y; Wen, T; Rothenberg, ME. Science Translational Medicine. 2020; 12:eaaz7773.


Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. Wen, T; Aronow, BJ; Rochman, Y; Rochman, M; Kiran, KC; Dexheimer, PJ; Putnam, P; Mukkada, V; Foote, H; Rehn, K; Darko, S; Douek, D; Rothenberg, ME. The Journal of Clinical Investigation. 2019; 129:2014-2028.


Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Kottyan, LC; Davis, BP; Sherrill, JD; Liu, K; Rochman, M; Kaufman, K; Weirauch, MT; Vaughn, S; Lazaro, S; Rupert, AM; Abonia, JP; Martin, LJ; Harley, JB; Rothenberg, ME. Nature Genetics. 2014; 46:895-900.


Treatment of patients with the hypereosinophilic syndrome with mepolizumab. Rothenberg, ME; Klion, AD; Roufosse, FE; Kahn, JE; Weller, PF; Simon, H; Schwartz, LB; Rosenwasser, LJ; Ring, J; Griffin, EF; Haig, AE; Frewer, PI H; Parkin, JM; Gleich, GJ; Grp, MH E S S. The New England journal of medicine. 2008; 358:1215-1228.

Building and implementing a research infrastructure for eosinophilic gastrointestinal diseases. Furuta, GT; Dellon, ES; Straumann, A; Gonsalves, N; Rothenberg, ME; Hirano, I. Journal of Allergy and Clinical Immunology. 2024; 153:1536-1539.

From the Blog

Tale of Two Studies Shows Mixed Progress Against EoE
Asthma and Allergy

Tale of Two Studies Shows Mixed Progress Against EoE

Marc E. Rothenberg, MD, PhD, Margaret H. Collins, MD6/26/2024

Researchers Produce Annotated Molecular Map of Eosinophilic Esophagitis
Genomics and Development

Researchers Produce Annotated Molecular Map of Eosinophilic Esophagitis

Marc E. Rothenberg, MD, PhD, Leah C. Kottyan, PhD ...1/26/2024

TSLP Inhibitors Emerge as Potential Therapy for Eosinophilic Esophagitis
Asthma and Allergy

TSLP Inhibitors Emerge as Potential Therapy for Eosinophilic Esophagitis

Marc E. Rothenberg, MD, PhD, Yrina Rochman, PhD9/12/2023

Wider Search Needed to Better Treat Eosinophilic Food Allergy
Asthma and Allergy

Wider Search Needed to Better Treat Eosinophilic Food Allergy

Marc E. Rothenberg, MD, PhD, Kara Kliewer, RD, PhD6/16/2023

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating